• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 2, 2018

View Archived Issues

2017 was a record-setting year for FDA approval of new molecular entities

It appears that the biopharmaceutical industry's innovation engine is back on track and making up for its poor return on research investments last year when only 22 new molecular entities (NMEs) received the FDA's Center for Drug Evaluation and Research (CDER) green light, the fewest number for five years. (See BioWorld Insight, Dec. 27, 2016.) Read More

Atara gets FDA go-ahead for EBV cell therapy

An off-the-shelf T-cell therapy for people with rituximab-refractory Epstein-Barr virus (EBV) flagged by the FDA for both orphan and breakthrough status is headed into dual phase III trials after the agency green-lighted its developer, Atara Biotherapeutics Inc., to make the move. Earlier data on the candidate, tabelecleucel, formerly known as ATA-129, suggests it might significantly improve the odds of survival for people who develop lymphomas and other lymphoproliferative disorders caused by EBV after solid organ or blood cell transplants. Read More

Fewer CRLs in 2017, Heplisav-B, Parsabiv rebound, but Neulasta biosimilars, RA therapies challenged

Although the number of complete response letters (CRLs) issued by the FDA to biopharmaceutical companies in 2017 dipped by 23 percent compared to the prior year, extensive planning and robust studies once again offered no foolproof promise of commercial glory. Read More

China's Legend to partner with Janssen on anti-BCM CAR T

SHANGHAI – Nanjing-based Legend Biotechnology Corp. has partnered with Janssen Biotech Inc., a subsidiary of Johnson & Johnson, to develop in CAR-B38M, a promising chimeric antigen receptor T cell (CAR T) therapy for multiple myeloma that targets B-cell maturation antigen (BCMA). Read More

Sheep model shows brain urea may be target in early Huntington's disease

Lowering brain levels of urea and/or ammonia might be a viable new therapeutic target for Huntington's disease (HD), according to the findings of a New Zealand study reported in the Dec. 11, 2017, online edition of Proceedings of the National Academy of Sciences. Read More

Sluggish progress in SCD 'about to change' as wins pile up, effort broadening

Chimeric antigen receptor T-cell data from Bluebird Bio Inc. (and partner Celgene Corp.) stole the show recently at the American Society of Hematology (ASH) meeting, but the firm's results in sickle cell disease (SCD) may get more attention as time goes on. Not much is heard about the indication overall, CEO Nick Leschly acknowledged. Read More

Holiday notice

BioWorld's offices were closed in observance of New Year's Day. Read More

Other news to note

Ignyta Inc., of San Diego, said the FDA cleared its IND application for RXDX-106, an oral immunomodulatory agent and TAM inhibitor designed to treat patients with solid tumors. Read More

In the clinic

Fervent Pharmaceuticals Inc., of Greenville, N.C., submitted an IND application to the FDA for FP-101, its lead drug candidate for treating menopause symptoms, especially hot flashes. Read More

Regulatory front

The FDA said drugmakers have withdrawn more than 110 abbreviated new drug applications due to cessation of marketing, including heparin sodium for injection by Watson Labs Inc., a division that is now part of Teva Pharmaceuticals of Horsham, Pa. Read More

Financings

Saniona AB, of Copenhagen, entered a convertible notes funding agreement with Nice & Green S.A., a private Swiss financing firm, under which the latter committed to subscribe up to SEK72 million (US$8.7 million) in convertible notes in individual tranches of SEK6 million each over a 12-month period subject to prolongation by Saniona. Read More

Bench Press: BioWorld looks at translational medicine

Scientists have identified antibodies that stimulated bone marrow cells to differentiate into microglia-like cells and migrate to the brain, where they reduced the levels of amyloid plaque in mouse models of Alzheimer's disease. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe